◆Lorviqua Tab= Lorviqua is a treatment that received domestic marketing authorization as monotherapy to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC).

The company applied for reimbursement after receiving approval from the Ministry of Food and Drug Safety on July 29th. The Health Insurance Review and Assessment Service deliberated the agenda at the Cancer Disease Deliberation Committee on January 12th, and at the Drug Reimbursement Evaluation Committee on April 7th. At the time, HIRA had determined the drug adequate for reimbursement and waived pharmacoeconomic evaluations. The drug is listed in 7 of the A7 countries.